Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

C. E. Gollins (Lead / Corresponding author), A. Shah, K. Sinha, S. Khan, N. Paul, B. Meeajun, R. A. Abbott, C. Blasdale, H. Cooper, C. A. Harwood, F. Ismail, J. T. Lear, L. Mackintosh, S. McCormack, C. M. Perrett, C. M. Proby, A. Durack, R. Patalay, R. N. Matin

Research output: Contribution to journalLetterpeer-review

Abstract

Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.

Original languageEnglish
Pages (from-to)394-396
Number of pages3
JournalBritish Journal of Dermatology
Volume183
Issue number2
Early online date2 Mar 2020
DOIs
Publication statusPublished - 1 Aug 2020

Fingerprint Dive into the research topics of 'Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK'. Together they form a unique fingerprint.

Cite this